A new federal drug-pricing model could change how Maryland and Pennsylvania pay for some prescription medicines in Medicaid, but residents should not expect every covered medication to suddenly carry a new pharmacy-counter price. The Centers for Medicare & Medicaid Services announced September 18 that all 50 states, the District of Columbia and Puerto Rico have applied to participate in the GENEROUS model, which is designed to use supplemental manufacturer rebates to bring Medicaid's net prices for certain drugs closer to prices paid in selected other countries.
CMS says 40 states and Puerto Rico have already signed participation agreements, with remaining states given until September 30 to finalize participation. The agency estimates the model could save taxpayers $64.3 billion over 10 years, although that figure is a federal projection rather than a guaranteed result. The program began in January 2026 and is scheduled to operate for five years. Participation is voluntary for states and drug manufacturers, which means the final savings will depend on which manufacturers participate, which drugs are included and how states implement the rebate arrangements.
The mechanics matter because Medicaid drug pricing is different from a retail discount program. Under GENEROUS, participating manufacturers make covered outpatient drugs available to participating state Medicaid programs at pricing tied to what selected other countries pay. States then invoice manufacturers for supplemental rebates. CMS shares in those rebates through adjustments to the federal share of Medicaid payments. The model is therefore primarily a change in the net amount governments pay after rebates, not a promise that every Medicaid beneficiary will see a lower copayment at the pharmacy counter.
That distinction is particularly relevant in Maryland, where the Department of Health says Medicaid covers about 1.5 million people, nearly one in four residents. Maryland already operates most Medicaid care through the HealthChoice managed-care system, and prescription coverage is integrated into a larger framework of state formularies, managed-care organizations and federal rebate rules. If GENEROUS lowers the state's net drug costs, the benefit may show up through budget savings, reduced pressure on program spending or greater room to finance other health services rather than through a visible price reduction on a member's receipt.
Pennsylvania's Medicaid program is even larger in absolute terms. State data for August 2026 show about 2.87 million people receiving Medicaid. The program reaches every part of the state, including more than 234,000 people in Allegheny County alone. Pennsylvania is simultaneously preparing residents for other federally required Medicaid changes scheduled for 2027, which means the drug-pricing initiative arrives during a period of broader administrative change. Those issues should not be conflated: GENEROUS concerns prescription-drug net pricing, while separate federal rules affect eligibility and coverage requirements for some enrollees.
For beneficiaries, the key question is access. Lower net prices can make expensive drugs less burdensome for state programs, but a rebate model can also influence formulary negotiations and purchasing strategy. CMS says the model is intended to preserve or enhance quality of care. States will still have to manage coverage rules, preferred-drug lists and utilization controls under Medicaid law. A resident taking a specific medicine should therefore not change treatment or expect a coverage change based only on the announcement. Any meaningful member-level change would need to be communicated through the state Medicaid program or the member's managed-care plan.
For state budgets, the potential impact is more direct. Prescription drugs are a recurring Medicaid expense, and specialty medicines can be particularly costly. If supplemental rebates materially reduce net prices, states could retain savings after the federal-state financing split. CMS argues those savings could free resources for other priorities. The actual Maryland and Pennsylvania budget effect, however, will depend on enrollment, the mix of covered drugs, manufacturer participation and the rebate amounts negotiated through the model.
The model also creates strategic questions for drug manufacturers. Medicaid already has a statutory rebate program that requires manufacturers to provide rebates in exchange for state coverage of their outpatient drugs. GENEROUS adds a voluntary layer designed to align net prices with selected international benchmarks. Manufacturers will have to decide whether participation offers enough market access or predictability to justify additional rebates. Because the model is voluntary on both sides, a company's decision not to participate could limit the reach of the initiative for its products.
Maryland and Pennsylvania officials will also have to reconcile the model with existing pharmacy-benefit arrangements. Medicaid programs use preferred-drug lists, prior authorization and managed-care contracts to control costs and ensure access. A new supplemental rebate can alter the economics behind those tools without necessarily changing the outward rules immediately. That is why the first signs of impact may appear in state budget documents, rebate reports and formulary updates rather than at the pharmacy counter.
The September 30 agreement deadline is the next immediate milestone. CMS had not, in the public materials reviewed by The American Desk, clearly identified the final signed-agreement status of Maryland and Pennsylvania individually. Both states are included in the group of all states that applied, but residents should wait for state or CMS confirmation before assuming every operational step is complete.
For now, the most important takeaway is that GENEROUS is a financing and purchasing reform, not a universal consumer discount. If it works as CMS projects, Maryland and Pennsylvania could spend less on some Medicaid drugs and potentially redirect savings elsewhere in their health programs. Whether beneficiaries experience broader access, fewer restrictions or other changes will depend on the drugs included, the agreements signed and the way each state implements the model over the coming months.